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Abstract 
A novel fluidic-based electrochemical ELISA platform is descried for estimation of the bladder 
cancer protein markers nuclear mitotic apparatus protein 1 (NUMA1) and complement factor H-related 
1 (CFHR1). The platform uses an off-site chamber for a sandwich immunoassay and performs the 
electrochemistry on-chip in a separate chamber. The off-site matrices were connected to the sensor chip 
in a manner that the sensors were exposed only to the final electroactive product for signal detection, 
thus avoiding interference from other molecules present in the sample. Two off-site matrices using 3D 
polymethyl methacrylate (PMMA) sheets and 2D polycarbonate (PC) membranes modified with the 
desired antibodies were investigated. Antibodies for NUMA1 and CFHR1 were utilized for the 
immunoassay and hair comb structured gold electrodes were used for sensing. Results in 10% synthetic 
urine reveal that the system can detect NUMA1 and CFHR1 in the 1–100 ng/ml range with high 
sensitivities of 260 nA/(ng/ml) and 310 nA/(ng/ml), for NUMA1 and CFHR1, respectively; negligible 
interference from the diluted urine and other molecules has been observed. A fully automated fluidic 
prototype has also been developed to demonstrate that automation of the process and multiplexing of 
detection can be achieved in a small footprint benchtop device. The use of off-site matrix-based platforms 
paves the way towards a new generation of electrochemical immunosensors for biomarker estimation 
with negligible non-specific interactions and false signals in complex samples.  
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1. Introduction 
Cancer is a life-threatening disease and its various types may affect almost any human organ. 
Among various cancer types, bladder cancer (BCa) is one of the major cancers affecting around 430,000 
people every year worldwide (Ferlay et al., 2013). Bladder’s cystoscopic examination along with voided 
urine cytology (VUC) are the gold standard tests for its preliminary clinical diagnosis (Nakamura et al. 
2009; Têtu 2009; Trivedi and Messing 2009). However, cystoscopy, which enables biopsy of doubtful 
lesions and viewing of bladder lining for histopathological analysis and staging, is invasive, expensive, 
an uncomfortable procedure and may necessitate anesthetization. VUC testing, on the other hand, which 
has shown sensitivities in the 13–75% range with specificities in the 85–100% range (Miyake et al. 2012; 
van Rhijn et al. 2005) depends on microscopic visualization of shed cancer cells in voided urine, and 
requires trained screeners for assessments. Also, it is non quantitative and has low sensitivity, especially 
for low-grade tumors (Kumar et al. 2006). Therefore, a wide range of alternative procedures and markers 
have been proposed and studied for the detection of recurrent bladder tumors. The introduction of non-
invasive urine-based markers such as bladder tumor antigen (BTA), nuclear matrix protein 22 (NMP22), 
along with Immunocyt and fluorescence in situ hybridization (FISH), has yielded improved diagnostic 
accuracy (Parker and Spiess 2011). Also, for better treatment and management of this disease, early 
detection using non-invasive urine tests are greatly desirable and diagnosis via molecular assays could 
provide significant advance.  
For biomarker-based diagnosis, bladder tumor antigen test involving detection of urinary 
complement factor H-related proteins (Kinders et al. 1998) and nuclear matrix protein-22 test involving 
detection of nuclear mitotic apparatus protein 1 (NUMA1) (Miyake et al. 2012) in voided urine samples 
are most common and FDA approved. However, urinary BTA and NMP-22 tests have shown diagnostic 
sensitivities in the 29–83% and 47–100% ranges with specificities in the 56–86% and 55–98% ranges, 
respectively. Thus, more efforts need to be made in order to improve these tests (Grossman et al. 2005; 
Miyake et al. 2012).  
The use of emerging biosensor technology in biomarker detection could be instrumental in early 
BCa cancer detection, enabling more effective treatments and hence resulting in improvements in patient 
quality of life and overall chance of survival. Application of biosensors in cancer diagnostics has several 
advantages over other diagnostic methods including increased assay speed, non-invasive procedure, 
flexibility, capability for multi-target analysis, automation, and reduced cost of testing (Arya and 
Bhansali 2011). For BCa diagnosis, estimation of NMP22 and BTA in urine has provided a simple non-
invasive way for identifying BCa patients, which is also suitable for the diagnosis and follow-up of BCa 
cases with high rate of relapse. Till date, for real sample testing, optical enzyme-linked immunosorbent 
assay (ELISA) has shown great success and is most commonly used method of screening target proteins 
in real samples (Bettazzi et al. 2012). However, due to its limitation in sensitivity, high cost of 
instrumentation and non-portability, there is an urgent need to develop new technologies that enable easy 
screening of high-risk individuals for cancer at an early stage. The combination of immunological 
techniques with electrochemical detection (electrochemical ELISA) is a promising clinic detection 
method (Arya et al. 2017a; Arya et al. 2017b) with high sensitivity and specificity, requirement of less 
time, and low cost. Usually electrochemical ELISA involves the binding of biomolecules and 
electrochemical signal recognition on the same sensor surface (Kokkinos et al. 2016; Pan et al. 2017; 
Zhang et al. 2016); however, binding of biomolecules on sensor surfaces may result in degradation of 
their electrochemical properties and the application of an input electrochemical signal may also affect 
the sensing layer.  
To avoid the mentioned issues and to improve signal sensitivity with low background noise, the 
present work describes the concept of an integrated sensor chip, where an off-site matrix is employed for 
on-chip electrochemical biosensing. Two different types of matrices are described to show the utility of 
the proposed concept as a new biosensor platform. This has been achieved by using a microfluidic based 
electrochemical platform, where separation of assay chamber and detection chamber with innovative 
surface chemistry, microfluidic design and electrochemical detection technique has been adopted and 
described. The bladder cancer biomarkers NUMA1 and complement factor H-related 1 (CFHR1) have 
been used as test cases. It should be noted that currently there are no reported biosensors for these two 
markers. The study is expected to pave way for the development of inexpensive, accurate, and reliable 
diagnostic devices for bladder specific cancer biomarker detection. Also, a number of biomolecules can 
be immobilized selectively in an array format to achieve simultaneous multimarker detection and best 
performance. 
 
2. Materials and Methods 
2.1 Chemicals 
NUMA1 monoclonal antibody (M01), clone 1C5, NUMA1 human recombinant protein (Q01), 
glutathione S-transferase (GST) purified rabbit polyclonal antibody, complement factor H-related 1 
(CFHR1) recombinant protein (P01), CFHR1 monoclonal antibody (M01), clone 4D7, CFHR1 purified 
MaxPab rabbit polyclonal antibody (D01P) were purchased from Abnova (Taiwan); goat anti-rabbit IgG 
H&L (alkaline phosphatase) from Abcam (UK); 4-aminophenyl phosphate monosodium salt (4APP) 
from Santa Cruz Biotechnology (USA); polycarbonate (PC) membrane filter containing 20 µm holes was 
procured from Sterlitech (USA); PBS based Starting Block T20 (PBSTSB) from Fisher Scientific (UK); 
PBST20 from Sigma (UK). 1-fluoro-2-nitro-4-azidobenzene (FNAB) was from Apollo Scientific (UK); 
synthetic urine from Testclear (USA). Other analytical grade chemicals were utilized as received.  
 
2.2 Gold sensor chips development 
Gold sensor chips with a hair comb structure were developed via photolithography patterning and 
gold deposition technique on silicon oxide coated silicon wafers as described in a previous report (Pui et 
al. 2013). For the hair comb design, comb fingers of 5 µm width and 3200 µm length with 25 µm spacing 
were patterned over a length of 5500 µm and connected via a base electrode of 200 µm. Counter gold 
electrode and pseudo-reference gold electrode were also deposited on the same chip. The developed hair 
comb shaped gold sensor chips were washed with ethyl alcohol, acetone and water, and then cleaned 
using UV-ozone for 30 min before use.  
 
2.3 Formation of PMMA chip and PC membrane and their modification  
To make a 3D polymethyl methacrylate (PMMA) chip for the off-site matrix, 11 mm x 12 mm 
PMMA with 3 mm thickness was laser engraved in an area of 6.5 mm x 7.5 mm to cover the active area 
of the sensor. Such engraving resulted in the formation of cuboidal pillars (Fig 1a: black dots on white 
background), thus making 3D structures. Two holes were also made at diagonal end of engraving to 
create fluidic channel and incubation chamber. Off-site 2D matrix made of poly carbonate (PC) 
membrane was prepared via laser cutting of large filter into smaller matrix of oval shape with longer 
width of 9 mm and smaller width of 7 mm (Fig 1b). Prior to FNAB modification, the PMMA matrix was 
washed and sonicated in IPA for 10 min and then washed using water jet before drying using nitrogen 
blow. The laser cut membrane was first cleaned with water and methanol following by drying in air. For 
FNAB modification, 1 mg/25 µl of FNAB in MeOH was found to be optimal as higher concentration 
resulted in the same response. For 3D PMMA chip and 2D PC membrane, 50 µl and 25 µl solutions, 
respectively, were found to be enough for complete coverage. The solutions were allowed to dry in dark 
(Fig 1c and 1d). After drying, the yellow colored matrices were exposed in an UV irradiation system 
from Oriel Instruments, USA (Fig 1e and 1f: matrix after exposure) and washed with methanol to remove 
excess FNAB (Fig 1g and 1h). For UV exposure at 75 W power, 30 min minutes were found to be 
optimum. FNAB during UV exposer resulted in production of highly reactive nitrene group, which 
underwent grafting on hydrocarbon chain of PMMA/PC surface via covalent bond formation (Bora et al. 
2006). Change in color of matrices (Fig 1) suggested successful FNAB modification. 
 
  
Fig. 1. PMMA/PC matrix at various stages of FNAB modification (a, b) blank laser engraved/cut matrix, 
(c, d) after dropping FNAB and drying in dark, (e, f) after UV exposure and (g, h) after washing with 
methanol and drying, (i) schematic for matrix modification and antibody binding, (j) schematic for matrix 
assembly and bioassay at each step 
 
2.4 Immobilization of antibodies on FNAB modified matrices and chip assembly. 
For antibody binding, 5 µg/ml solution of CFHR1 and NUMA1 antibodies were prepared in 
phosphate buffer (1x) as a stock solution. For covalent immobilization, 50 µl of anti-NUMA1 antibody 
and 25 µl of anti-CFHR1 antibody solutions in phosphate buffer were dispensed on the PMMA and PC 
matrices, respectively and were kept at 37 C for 2 h. During incubation, surface bound FNAB reacts 
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with the amino groups of antibody and resulted in its covalent binding via nucleophilic replacement 
reaction on thermally active fluoro group (Arya et al. 2006; Arya et al. 2007; Bora et al. 2006). Antibody 
modified matrices were washed with PBS tween solution and with PBS to remove physically unbound 
antibodies. Anti-NUMA1/FNAB/PMMA and anti-CFHR1/FNAB/PC chips were then assembled onto a 
glass slide using 140 µm thick double side tape and the fluidic connections were made. Incubation for 
30 min with PBSTSB blocker was performed for blocking any available free spaces on the matrices. The 
anti-NUMA1/FNAB/PMMA and anti-CFHR1/FNAB/PC electrodes were thus formed and stored in a 
humidity chamber in the fridge until use. Figure 1i shows the schematic for matrix modification and 
antibody binding. 
 
2.5 Sandwich electrochemical immunoassay and signal detection 
For antigen detection (NUMA1 on PMMA matrix and CFHR1 on PC matrix), the anti-
NUMA1/FNAB/PMMA and anti-CFHR1/FNAB/PC matrices were incubated with desired 
concentrations of antigen in PBS buffer/10% synthetic urine in PBS. Incubation for 30 min was found 
sufficient for adequately high and reproducible responses, thus 30 min incubation was used for each step 
unless otherwise stated. After antigen incubation, the chips were washed with PBST20. The chips were 
then incubated with 5 µg/ml secondary antibody (from rabbit) solution in PBST20 for 30 min. After 
incubation, the chips were washed again with PBST20, followed by 30 min incubation with 10 µg/ml 
alkaline phosphatase (ALP) tagged IgG from rabbit solution in PBST20. After IgG-ALP binding chips 
were washed with PBST20 and finally incubated with 4APP (2 mg/ml) in 100 mM deoxygenated tris-
HCl buffer (pH 9) containing MgCl2.6H2O (4 mg/ml) for 20 min followed by differential pulse 
voltammetric (DPV) signal recording. DPV scan was recorded at step potential of 10 mV, amplitude of 
25 mV, and interval time of 0.1 s. DPV scans were performed using Nova 2.1 software on a µAutolab 
III / FRA2 potentiostat/galvanostat (Metrohm, Netherlands). 10% urine without specific antigen was 
used as control and 10% urine with non-target antigen or proteins were used for interference studies. All 
measurements were repeated on at least three chips and the standard deviation represented via error bars. 
Fig.1j shows the schematic bioassay at each step. 
 
2.6 Prototype design 
Conceptual design for prototype system was made using a microfluidic system with integrated 
assay and detection chambers (Fig 2b). The prototype was designed to be equipped with a rotating bay 
to carry reagents, fluidic lines for carrying reagents to assay chamber (Fig 2a) to perform the bioassay, 
peristaltic pump for controlled speed fluidics valves to control the flow direction, sensor chip for signal 
detection, control board to control all process automatically and PC to run the program and to display the 
results. Prototype was designed for handling 4 chips at the same time and multiple assay chambers can 
be utilized for multiplexing. For biomarker estimation, the assay chamber with specific antibodies was 
used to capture the desired protein biomarker. A sandwich immunoassay was then programmed with the 
biomarker and a protein-specific, enzyme labeled detection antibody. In the last step of the assay, added 
substrate was converted to an electrochemically active form by the enzyme, which is transferred via 
pump control to the detection chamber, where the electrochemical signal is measured. During processing 
of all bioassay steps, reagents were flown through the assay chamber and the extra solution was passed 
to the waste chamber without moving through the detection chamber. In this way the detection chip 
remained pristine to produce high sensitivity signals with low background noise, thus reducing false 
positives. Fig. 2 shows the schematic of matrix assembly and prototype concept. 
 
 Fig. 2 schematic of (a) PC and PMMA based matrix assembly and (b) prototype concept.  
 
3. Results and discussions 
3.1 Off-site matrix with on-chip detection platform and its working principle 
Figure 1 shows the general schematic for FNAB based matrix modification and antibody binding 
along with optical images of 3D laser engraved PMMA and 2D PC matrices at various stages of FNAB 
modification. The color variation at different stages suggested effective FNAB modification of matrix. 
For antibody binding, FNAB works as cross-linker and bind to matrix through its azide group and to 
antibody through its thermally labile fluoro group. Covalent antibody binding via nucleophilic attack by 
amino group of antibody at reactive thermally labile fluoro group on matrix was achieved at 37 C (Arya 
et al. 2006; Arya et al. 2007; Bora et al. 2006). On assembling onto glass surface using double side tape 
and attached to sensor chip via fluidic tubings, it provided off-site sensor for on-chip detection. Fig. 2 
shows the general schematic sensor setup assembly along with the schematic for prototype concept. As 
immunoassay steps occur on matrix and only final electroactive product was moved to sensor chip, it 
resulted in better sensitivity and improved reproducibility. 
  
3.2 Blank Gold electrodes with hair comb structure chip characterization and contact angle 
measurement 
Cyclic voltammetry (CV) and electrochemical impedance spectroscopy (EIS) in potassium 
ferrocynide (5 mM) / potassium ferricynide (5 mM), [Fe(CN)6]
3-/4-, in PBS was utilized for 
characterization of blank gold electrodes with hair comb structures. The CV spectra in Fig 3 show 
prominent oxidation and reduction peaks with comparable currents and semi reversible behavior, 
indicating high conductivity and sensitive chip response. Furthermore, 5 different electrodes showed the 
same CV and EIS responses, indicating a reliable, reproducible fabrication process and can be employed 
for different concentration on different chip response for comparison.   
PMMA/PC matrices at various stages of sensor fabrication were characterized via contact angle 
measurements (Fig 3c-j) using an in-house built optical angle measurement system (Miodek et al. 2015). 
For measurement, matrices were placed on the stage using double side tape and a 10 µl of water drop 
was dispensed on the electrode with the dispensing system. The wetting of surface was then captured 
using a Nikon p520 camera. Contact angle was measured using a screen protractor version 4.0 procured 
from Iconico. Fig 3 shows blank PMMA/PC matrix (c, d), after FNAB modification (e, f), after antibody 
binding (g, h), and after blocking with PBSTSB (i, j). Increase in contact angle value for FNAB 
modification along with color change indicated successful FNAB binding. Decrease in contact angle 
value after antibody binding confirms its immobilization and may be attributed to the hydrophilic nature 
of antibody. Further, decrease in contact angle value after blocking suggested the coverage of 
hydrophobic free spaces on matrix by hydrophilic proteins present in blocker solution. 
  
Figure 3. Characterization of blank gold electrodes using (a) CV recording at 50 mV/s scan rate and (b) 
at EIS. Contact angle images for PMMA/PC matrix at various stages of sensor fabrication blank 
PMMA/PC matrix (c, d), after FNAB modification (e, f), after antibody binding (g, h), and after blocking 
with PBSTSB (i, j). 
 
3.3 NUMA1 concentration in PBSTSB and 10% urine studies on SB-Anti-NUMA1/FNAB/PMMA 
electrode 
Fig. 4a and 4c show the anti-NUMA1/FNAB/PMMA/glass electrode response for different 
NUMA1 concentrations (1 ng/ml – 100 ng/ml) in PBSTSB and 10% urine in PBSTSB, respectively, 
when tested via DPV scans. With increasing concentration, the response current was found to be 
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increasing, suggesting successful immunoassay. As concentration increases, amount of antigen capture 
increases, resulting in more secondary antibodies and ALP-IgG molecules binding and resulting in higher 
production of 4-amino phenol from ALP based conversion of 4APP, which then releases 2 electrons on 
electrochemical oxidation to quinonimide. Fig. 4b and 4d show the change in current response for 
different concentrations of NUMA1 in PBSTSB and 10% urine. It is clear that anti-
NUMA1/FNAB/PMMA/glass electrode can be used for sensing NUMA1 in buffer and in 10% urine in 
1 ng/ml – 100 ng/ml range with sensitivity of 250 nA/(ng/ml), and 260 nA/(ng/ml), respectively and 
follow linear relationships of ΔI (µA) = 1.2 + 0.25 cNUMA1 (ng/ml) and ΔI (µA) = 0.29 + 0.26 cNUMA1 
(ng/ml) in PBSTSB and in 10% urine, respectively. Error bars representing repeated measurements 
reveals the consistency within 4% error and the detection limit estimated using 3SD of blank/sensitivity 
is found to be 1.58 ng/ml and 1.29 ng/ml in PBSTSB and in 10% urine, respectively. Only a slightly 
higher background signal is observed in urine, while similar variation in peak current and sensitivity 
suggest that the sensor can be employed in real samples.  
To validate the off-site PC matrix based sensor, 2D PC membrane based anti-
CFHR1/FNAB/PC/glass electrode was tested for CFHR1 detection also in PBSTSB and in 10% urine. 
Fig. 5a and 5c show the anti-CFHR1/FNAB/PC/glass electrode response for varying CFHR1 
concentrations (1 ng/ml – 100 ng/ml) in PBSTSB and 10% urine, respectively, when tested via DPV 
scans. Similar to NUMA1, increasing concentration of CFHR1 showed increased response in DPV scans 
and attributed to increasing concentration of 4-amino phenol from ALP based conversion of 4APP. Fig. 
5b and 5d show the change in current response for different concentration of CHRF1 in PBSTSB and 
10% urine. It is clear that anti-CFHR1/FNAB/PC/glass electrode can be used for sensing CFHR1 in 
PBSTSB and urine in the 1 ng/ml – 10 ng/ml range with a sensitivity of 320 nA/(ng/ml) and 310 
nA/(ng/ml), respectively and follow linear relationships of ΔI (µA) = 3.36 + 0.32 cCFHR1 (ng/ml) and ΔI 
(µA) = 1.41 + 0.31 cCFHR1 (ng/ml) in PBSTSB and in 10% urine, respectively. Error bars representing 
repeated measurements reveals the consistency within 5% error and the detection limit estimated using 
3SD of blank/sensitivity is found to be 1.13 ng/ml and 0.97 ng/ml for CFHR1 in PBSTSB and in 10% 
urine. Similar to NUMA1, slightly higher background for urine sample suggested some interference from 
urine contents. Results suggest that measurements for NUMA1 and CFHR1 in urine samples using off 
site matrix connected to sensor chip via fluidic line based system may provide new and better biosensor 
platform for measuring of protein markers in urine. 
 
 
 
Fig. 4. DPV spectra obtained on anti-NUMA1/FNAB/PMMA matrix for NUMA1 concentrations in (a) 
PBSTSB, (c) 10% urine in PBSTSB 1 ng/ml–100 ng/ml. NUMA1 concentration linearity curve for 
normalized current obtained by subtracting blank current value for (b) PBSTSB and (d) 10% urine in 
PBSTSB. 
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Fig. 5. DPV spectra obtained on anti-CFHR1/FNAB/PMMA matrix for CFHR1 concentrations in (a) 
PBSTSB, (c) 10% urine in PBSTSB 1 ng/ml–100 ng/ml. CFHR1 concentration linearity curve for 
normalized current obtained by subtracting blank current value for (b) PBSTSB and (d) 10% urine in 
PBSTSB. 
 
3.4 Interference studies and prototype response 
Anti-NUMA1/FNAB/PMMA/glass electrode was tested for interference from CFHR1, TNF- 
and HER2 at concentrations of 100 ng/ml. Fig 6a shows the DPV results, compared with the response 
with 50 ng/ml NUMA1, i.e. half the concentration of the interferents. Similarly anti-
CFHR1/FNAB/PC/glass electrode was tested for interference from NUMA1, TNF- and HER2 at 
concentrations of 100 ng/ml and compared with CFHR1 at concentration of 50 ng/ml (Fig 6b). From Fig. 
6, it is clear that electrodes do not show significant interference and are specific for their respective 
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antigen. Further, the electrodes were tested for 3 weeks shelf life at 4 C and found to show more than 
95% response even after three weeks. 
 
 
Fig. 6 (a) DPV scans for PBSTSB (i), 100 ng/ml of CFHR1 in PBSTSB (ii), 100 ng/ml of TNF- in 
PBSTSB (iii), 100 ng/ml of HER2 in PBSTSB (iv), 50 ng/ml of NUMA1 in PBSTSB (v). (b) DPV scans 
for PBSTSB (i), 100 ng/ml of NUMA1 in PBSTSB (ii), 100 ng/ml of TNF- in PBSTSB (iii), 100 ng/ml 
of HER2 in PBSTSB (iv), 50 ng/ml of CFHR1 in PBSTSB (v). (c) Image of prototype developed and (d) 
DPV scans for 4APP in Tris-HCl buffer (i) PBSTSB (ii) and 50 ng/ml NUMA1 in PBSTSB (iii). 
 
Using developed procedure and platform, prototype was designed and developed with the help 
of TOMCOPY Pte Ltd (Fig 6c). The prototype was designed and the software developed in such way 
that it can control all steps automatically as programmed on display and can run one chip in continuous 
flow manner or can run multiple chips simultaneously in pulse mode, i.e. it will suck solution from 
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reagent bay and deliver to matrix with predefined speed and time and then move to 2nd chip for given 
instruction or wait till incubation period is over before doing 2nd step of assay. Prototype can be run in 
manual or automatic mode and can be operated directly from its screen or after connected to computer 
via USB cable and developed software. Further, it can be connected to an electrochemical system such 
as a potentiostat/galvanostat to run the measurement automatically at the last step via trigger control. 
During the assay, the solution after each incubation and washing solutions go directly to the waste 
chamber bypassing the sensor chip; only in the last step the solution from the matrix goes to the sensor 
chip (controlled delay time and flow rate) and triggers the connected electrochemical system for signal 
measurement. Initial results for NUMA1 (Fig 6d) suggest that the developed prototype is working as 
expected and the measurement system can be programmed for simultaneous assays in multiple sensors. 
To achieve best response from prototype, further optimization for immunoassay using prototype are still 
required and detailed work is under investigation and finding will be publish in future studies. 
 
4. Conclusions 
In conclusion, a fluidic connected off-site matrix based electrochemical ELISA biosensor 
platform has been developed where the interactions happen in a chamber separate from the sensing 
electrodes, enabling reduced electrochemical background signal. In validation of developed off-site 
matrix based platform, antibody-modified sensors exhibited linearity over the 1–100 ng/ml range, with 
sensitivities of 260 nA/(ng/ml), and 310 nA/(ng/ml), for NUMA1 and CFHR1 respectively in 10% urine 
samples. Further, electrodes showed detection limits in the diluted urine samples of 1.29 ng/ml and 0.97 
ng/ml for NUMA1 and CFHR1, respectively and showed good selectivity during interference studies. 
The linear ranges are comparable with the more cumbersome standard ELISA kits, which measure 
CFHR1 in the range 0.78-50 ng/ml and NUMA1 in the range 0.156-10 ng/ml. Although using diluted 
synthetic urine, the results here presented are extremely promising for the development of sensors for a 
whole range of protein biomarkers in complex samples. 
Furthermore, the use of both 3D PMMA matrix and 2D PC membrane matrix indicate that an off-
site matrix based platform can be employed with different types of matrices for wider application. Thus, 
the proposed system can pave the way for replacement of presently employed optical ELISA systems for 
biomarker sensing. A prototype has also been made showing electrochemical ELISA for multiple chips, 
which can be automated and performed easily.  
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